PUBLIC COMPANY
save$IOVAIOVANCE BIOTHERAPEUTICS, INC.
$IOVA14.21-0.11%San Carlos, CA, USupdated 1d ago
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
3Phase 21Phase 31Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
- —Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- phase2Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- phase1Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- phase3Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- phase2Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
- phase1Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
🐶 Hiring Signal
next earnings Nov 5, 2026
Where IOVANCE BIOTHERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 28
News
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 3d ago
- Cellectis quits CAR-T and pivots to ‘in vivo’ gene editingLong a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.biopharma_dive · 20d ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that